A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or Without Food

Phase 1 Recruiting 56 enrolled Boehringer Ingelheim

RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to establish the bioequivalence of Zongertinib tablets from two different manufacturers following oral administration.

Timeline

Start: 2026-09-09
Primary completion: 2026-12-15
Completion: 2026-12-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zongertinib	Small molecule	—	Oral

Indications

No indication recorded.